ATE246511T1 - Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndroms - Google Patents

Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndroms

Info

Publication number
ATE246511T1
ATE246511T1 AT97921307T AT97921307T ATE246511T1 AT E246511 T1 ATE246511 T1 AT E246511T1 AT 97921307 T AT97921307 T AT 97921307T AT 97921307 T AT97921307 T AT 97921307T AT E246511 T1 ATE246511 T1 AT E246511T1
Authority
AT
Austria
Prior art keywords
growth hormone
patient
igf
serum level
below normal
Prior art date
Application number
AT97921307T
Other languages
English (en)
Inventor
Kenneth M Attie
Lena M S Carlsson
Neil Gesundheit
Audrey Goddard
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE246511T1 publication Critical patent/ATE246511T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT97921307T 1996-05-03 1997-04-18 Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndroms ATE246511T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/643,212 US6207640B1 (en) 1994-04-07 1996-05-03 Treatment of partial growth hormone insensitivity syndrome
PCT/US1997/006652 WO1997041887A1 (en) 1996-05-03 1997-04-18 Treatment of partial growth hormone insensitivity syndrome

Publications (1)

Publication Number Publication Date
ATE246511T1 true ATE246511T1 (de) 2003-08-15

Family

ID=24579841

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97921307T ATE246511T1 (de) 1996-05-03 1997-04-18 Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndroms

Country Status (10)

Country Link
US (1) US6207640B1 (de)
EP (2) EP0914148B1 (de)
JP (1) JP2001510444A (de)
AT (1) ATE246511T1 (de)
CA (1) CA2252560C (de)
DE (1) DE69723982T2 (de)
DK (1) DK0914148T3 (de)
ES (1) ES2205211T3 (de)
PT (1) PT914148E (de)
WO (1) WO1997041887A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
ATE526401T1 (de) * 1999-01-14 2011-10-15 Bolder Biotechnology Inc Verfahren zur herstellung von proteinen mit freien cysteinresten
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO2004028568A1 (en) * 2002-09-27 2004-04-08 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor binding protein-4 and poly (ethylene glycol)
ATE536186T1 (de) * 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
KR101614983B1 (ko) * 2009-11-17 2016-04-22 입센 파마 에스.에이.에스 Ｈｇｈ 및 ｒｈｉｇｆ―１의 조합물을 위한 제제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5646113A (en) 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5824642A (en) * 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome

Also Published As

Publication number Publication date
WO1997041887A1 (en) 1997-11-13
JP2001510444A (ja) 2001-07-31
EP0914148B1 (de) 2003-08-06
PT914148E (pt) 2003-12-31
DE69723982T2 (de) 2004-07-22
US6207640B1 (en) 2001-03-27
ES2205211T3 (es) 2004-05-01
DK0914148T3 (da) 2003-11-24
EP1369125A1 (de) 2003-12-10
CA2252560A1 (en) 1997-11-13
DE69723982D1 (de) 2003-09-11
EP0914148A1 (de) 1999-05-12
CA2252560C (en) 2010-12-14

Similar Documents

Publication Publication Date Title
ATE203165T1 (de) Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndromes
TW264480B (de)
SE8703625D0 (sv) New medical use
EP0476044A4 (en) Treating disorders by application of insulin-like growth factors and analogs
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
ATE536186T1 (de) Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
ATE213499T1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
ATE246511T1 (de) Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndroms
JP2002536016A5 (de)
NO975360L (no) Peptid som inhiberer forhöyede triglyseridnivåer i blod og midler som inneholder nevnte peptid som aktiv komponent
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE165008T1 (de) Methode zur behandlung intestinaler krankheiten
DE69739737D1 (de) Methode zur Behandlung von Muskelkrankheiten
HU9202092D0 (en) An implantate composition containing biologically active protein, peptide or polypeptide
DE69326122D1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
ATE184489T1 (de) Behandlung fehlender milchabsonderung beim menschen
DE69113773D1 (de) Verwendung von 3-aryl-5-alkylthio-4H-1,2,4-triazolen zur Behandlung von Überreflexen infolge von Rückenmarkstrauma.
ATE251640T1 (de) Neues chondrozytprotein
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
DE69927599D1 (de) Verwendung von wachstumshormon und analoga davon für die behandlung von säugern mit familiärer hypercholesterolämie
DE3772047D1 (de) Pyrazin zur behandlung von haemodynamischen und metabolischen krankheiten.
Eijking Surfactant inhibition in acute respiratory failure: consequences for exogenous surfactant therapy
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0914148

Country of ref document: EP